Midodrine: use and current status in the treatment of hypotension

Br J Cardiol 2012;19:34–7doi:10.5837/bjc.2012.007 Leave a comment
Click any image to enlarge
Authors:

Midodrine is a sympathomimetic agent used in the treatment of hypotension resulting from various aetiologies. Debate around the use of midodrine recently increased after it was threatened with a licence withdrawal in the USA. The reason cited was a failure of the manufacturing drug companies to provide previously agreed post-market studies. Conversely, midodrine has never received a licence from the UK regulatory authorities.

We provide a review of its current status and a brief description of our own experience with midodrine over the last 11 years.

Pay to access this premium content £5

The BJC is introducing a small charge for some of its premium content. On purchase you will receive an email to access the article and have a downloadable PDF to keep. The PDF can be downloaded from a button on the sidebar. Please note the purchase of this article is for your personal use only.
By supporting us in this way, you are helping us to deliver high-quality services to healthcare professionals. We will continue to keep the majority of our content free of charge.


You can access this article without logging in.
But don't miss out on the many Benefits of our Membership. Register Now.
Already a member? Login Now.
THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT